Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Chevron Set to Expand Venezuela Operations as U.S. Signals Shift on Oil Sanctions 
China Considers New Rules to Limit Purchases of Foreign AI Chips Amid Growing Demand 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
TSMC Shares Hit Record High as AI Chip Demand Fuels Strong Q4 Earnings 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
U.S. Moves to Expand Chevron License and Control Venezuelan Oil Sales 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
California Attorney General Orders xAI to Halt Illegal Grok Deepfake Imagery 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
BYD Shares Rise in Hong Kong on Reports of Battery Supply Talks With Ford 
ALBANY, N.Y., April 06, 2017 -- AngioDynamics, Inc. (NASDAQ:ANGO) (the “Company”), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced the pricing of the previously announced underwritten public offering by certain of its stockholders (the “Selling Stockholders”) of 2.35 million shares of common stock at a price to the public of $16.20 per share. The Selling Stockholders will receive all of the net proceeds from this offering. No shares are being sold by the Company.
Barclays Capital Inc. is acting as the sole underwriter for the offering.
A shelf registration statement (including a prospectus) relating to the offering of common stock was filed with the SEC on October 3, 2013 and became effective on October 11, 2013. Before you invest, you should read the prospectus included in that registration statement and the documents incorporated by reference in that registration statement as well as the prospectus supplement related to this offering. You may obtain these documents for free by visiting EDGAR on the SEC website at www.sec.gov. When available, copies of the prospectus supplement and accompanying prospectus related to the offering may also be obtained by contacting Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, N.Y. 11717, or by telephone at 888-603-5847 or by emailing [email protected].
The offering of these securities will be made only by means of a prospectus supplement and the accompanying prospectus.
This release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer to buy the securities may be withdrawn or revoked, without obligation or commitment of any kind, at any time prior to notice of its acceptance given after the effective date of the shelf registration statement.
About AngioDynamics
AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories drainage products, thrombolytic products and venous products.
Trademarks
AngioDynamics and the AngioDynamics logo are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary.
Note on Forward-Looking Statements
This release may contain “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. By their nature, forward-looking statements involve risks and uncertainties because they relate to events and depend on circumstances that may or may not occur in the future, including risks and uncertainties relating to the consummation of the proposed offering by the Selling Stockholders and the risks identified, or incorporated by reference, in the prospectus supplement or accompanying prospectus. As a result of the foregoing considerations, you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release. All forward-looking statements are qualified in their entirety by this cautionary statement. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact: AngioDynamics Caitlin Stefanik (518) 795-1418 [email protected]
